SAN DIEGO--(BUSINESS WIRE)-- n-Lorem Foundation, a nonprofit organization providing the ultra-rare disease patients with free, lifetime supplies of individualized RNA-targeted medicines, today announced the appointment of Claire Grezemkovsky as its first-ever Director of Philanthropy.

Grezemkovsky joins the n-Lorem team with over 10 years of experience in corporate and foundation relations, working with notable organizations such as the Salk Institute for Biological Studies, W.M. Keck Observatory and most recently The Scripps Research Institute (TSRI). With a history of successful fundraising efforts in various fields of science ranging from biological sciences to ocean conservation, Grezemkovsky will oversee execution of n-Lorem’s fundraising portfolio development and management, donor relations and solicitation, and internal and external funding communications.

“With Claire Grezemkovsky joining our team, our efforts to provide rapid hope and treat more patients in desperate need becomes even more achievable,” said Dr. Stanley T. Crooke, Founder, CEO and Chairman, n-Lorem Foundation. “I’m delighted to welcome her to n-Lorem, and we look forward to her leadership in building new connections and fundraising, as we continue seeking new donors to aid us in our mission of creating a better future for patients and families affected by ultra-rare disease.”

Before starting her career in philanthropy, Grezemkovsky worked as an academic researcher and instructor at the University of California, Berkley. While there, she also received her Ph.D. in the History of Architecture. After graduating, Grezemkovsky became involved in more community service work, serving as a development committee chair for La Jolla’s Gillispie School, an advocacy team co-chair for Women Give San Diego and a member of the Jewish Family Service Behavioral Health Committee.

Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these desperate patients and families.

• Watch: n-Lorem Foundation Delivers Hope and Treatment for Patient with Ultra-Rare Disease
• Watch: n-Lorem Foundation: Creating a Better Future for Ultra-Rare, One Patient at a Time
• Watch: n-Lorem Foundation’s 1^st year of Progress

About n-Lorem Foundation

n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients with ultra-rare diseases (1 to 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. ASOs are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO, and former executive chairman of the board of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. To learn more about the n-Lorem Foundation, visit www.nlorem.org, and follow us on Twitter, Facebook, LinkedIn and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005110/en/